Skip to content
Screener

Avalo Therapeutics AVTX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$12.04M-13.5%
Alumis Inc. logo
Alumis Inc.ALMS
$15.95M+12.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
11.1%+0.1pp
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$1.69M+107%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$41.1M-10.7%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$7.71M-33.0%

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$31.5M-63.2%
Net income-$36.4M-75.1%
EPS (diluted)-$0.83+56.8%

Balance sheet

See full
Cash & equivalents$85.6M+101%
Total debt$242.0K-64.4%
Total equity$448.7M+329%
Total assets$490.8M+288%

Cash flow

See full
Operating cash flow-$20.0M-75.5%
CapEx-—
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$1.06B+987%
Enterprise value$974.89M+1,651%

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-36.3%—
Debt / equity0×0.0×
Current ratio19.3×+6.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Avalo Therapeutics’s 10-Q, filed November 9, 2020. Open the filing →

Filed
Nov 9, 2020, 4:35 PM EST
Fiscal quarter
Q3 FY2020
Calendar quarter
Q3 2020
Accession
0001628280-20-016113

FAQ

What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.